Compare AbbVie Inc (ABBV) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Equinor ASA — how do they compare? AbbVie Inc trades at $253.72 (market cap $449.91B), while Equinor ASA trades at $34.18 (market cap $77.42B). The key difference: AbbVie Inc is far larger — about 5.8× Equinor ASA's market cap, and Equinor ASA pays the higher dividend (4.48%). Which is the better fit depends on your goals.
| ABBV | EQNR | |
|---|---|---|
Market Cap | $449.91B | $77.42B |
Sector | Health | Energy |
52-Week High | $261.07 | $42.40 |
52-Week Low | $184.85 | $22.41 |
Enterprise Value | $513.38B | $89.19B |
Dividend Yield | 2.72% | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Equinor (EQNR) trades at $33.91, up 5.84% today, with a bearish technical signal despite recent earnings beats. The company shows solid cash flow from operations of $20.0B in 2025 and maintains a low EV/EBITDA of 2.21, but net income has declined to $5.04B. Recent strategic moves include acquiring BP's stake in Bay du Nord and expanding Norwegian gas production, while exiting non-core ventures like Japan offshore wind.
EQNR offers value with low valuation multiples and shareholder returns via dividends and buybacks, but faces risks from volatile energy prices and declining profitability. Analyst sentiment is mixed with 30% buy ratings, reflecting cautious optimism amid execution challenges and macroeconomic pressures on the oil and gas sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
